DESCRIBE <http://purl.uniprot.org/SHA-384/44C1D48EB68AF89F99C7062899B7F859F518AABCAED23B3D131953392E0831D1160E2E857E96E082FA11CDDC9828750F>

Subject	Predicate	Object
http://purl.uniprot.org/SHA-384/44C1D48EB68AF89F99C7062899B7F859F518AABCAED23B3D131953392E0831D1160E2E857E96E082FA11CDDC9828750F	http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/44C1D48EB68AF89F99C7062899B7F859F518AABCAED23B3D131953392E0831D1160E2E857E96E082FA11CDDC9828750F	http://www.w3.org/2000/01/rdf-schema#comment	"we propose CCDC6 as a biomarker of drugs sensitivity for MPMs. In case of MPMs expressing low levels of CCDC6 the addition of olaparib to cisplatinum and pemetrexed is expected to be highly beneficial. In case of MPMs expressing normal CCDC6 levels the sensitivity to olaparib can be restored by the addition of P5091."xsd:string
http://purl.uniprot.org/uniprot/#_A58B7332684F1F7BED6C6F2D9ABB70617A3F0E50B26BE754F5AE986F383A690B0A8F5BF75C6C21D8D818A2EB1C956F65	http://www.w3.org/1999/02/22-rdf-syntax-ns#subject	http://purl.uniprot.org/SHA-384/44C1D48EB68AF89F99C7062899B7F859F518AABCAED23B3D131953392E0831D1160E2E857E96E082FA11CDDC9828750F
http://purl.uniprot.org/uniprot/Q16204	http://purl.uniprot.org/core/mappedAnnotation	http://purl.uniprot.org/SHA-384/44C1D48EB68AF89F99C7062899B7F859F518AABCAED23B3D131953392E0831D1160E2E857E96E082FA11CDDC9828750F
http://purl.uniprot.org/uniprot/#_Q16204-mappedCitation-31447003	http://purl.uniprot.org/core/mappedAnnotation	http://purl.uniprot.org/SHA-384/44C1D48EB68AF89F99C7062899B7F859F518AABCAED23B3D131953392E0831D1160E2E857E96E082FA11CDDC9828750F